[go: up one dir, main page]

WO2008105533A1 - Adiponectin secretion-stimulating agent comprising capsinoid compound - Google Patents

Adiponectin secretion-stimulating agent comprising capsinoid compound Download PDF

Info

Publication number
WO2008105533A1
WO2008105533A1 PCT/JP2008/053637 JP2008053637W WO2008105533A1 WO 2008105533 A1 WO2008105533 A1 WO 2008105533A1 JP 2008053637 W JP2008053637 W JP 2008053637W WO 2008105533 A1 WO2008105533 A1 WO 2008105533A1
Authority
WO
WIPO (PCT)
Prior art keywords
stimulating agent
metabolic syndrome
mammal
adiponectin secretion
adiponectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053637
Other languages
French (fr)
Japanese (ja)
Inventor
Kaori Ono
Hitoshi Satoh
Yasufumi Furuhata
Naohiko Inoue
Yoshiko Matsunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of WO2008105533A1 publication Critical patent/WO2008105533A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Disclosed is a substance which can increase the production and secretion of adiponectin when administered orally to a mammal and therefore can prevent or ameliorate metabolic syndrome in the mammal. Specifically disclosed is an adiponectin secretion-stimulating agent for a mammal, which comprises a capsinoid compound and/or a degradation product thereof as an active ingredient. The adiponectin secretion-stimulating agent can be used in an oral pharmaceutical composition for the treatment of a subject suffering from metabolic syndrome or a composition for preventing and/or ameliorating metabolic syndrome without causing the decrease in the body weight of a subject suffering from metabolic syndrome.
PCT/JP2008/053637 2007-03-01 2008-02-29 Adiponectin secretion-stimulating agent comprising capsinoid compound Ceased WO2008105533A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007051588 2007-03-01
JP2007-051588 2007-03-01

Publications (1)

Publication Number Publication Date
WO2008105533A1 true WO2008105533A1 (en) 2008-09-04

Family

ID=39721355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053637 Ceased WO2008105533A1 (en) 2007-03-01 2008-02-29 Adiponectin secretion-stimulating agent comprising capsinoid compound

Country Status (1)

Country Link
WO (1) WO2008105533A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031729A1 (en) * 2011-08-26 2013-03-07 国立大学法人大阪大学 Prophylactic/therapeutic agent for cardiovascular complications of diabetes
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2629774A4 (en) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON A CHIMIOSENSORIAL RECEPTOR LIGAND

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246478A (en) * 1998-03-04 1999-09-14 Morinaga & Co Ltd New capsaicinoid-like material having ester bond
JP2001026538A (en) * 1999-07-13 2001-01-30 Morinaga & Co Ltd Food and pharmaceutical compositions containing novel capsaicinoid-like substances
JP2002114676A (en) * 2000-10-06 2002-04-16 Morinaga & Co Ltd Composition for improving endurance containing new capsaicinoid-like substance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246478A (en) * 1998-03-04 1999-09-14 Morinaga & Co Ltd New capsaicinoid-like material having ester bond
JP2001026538A (en) * 1999-07-13 2001-01-30 Morinaga & Co Ltd Food and pharmaceutical compositions containing novel capsaicinoid-like substances
JP2002114676A (en) * 2000-10-06 2002-04-16 Morinaga & Co Ltd Composition for improving endurance containing new capsaicinoid-like substance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IWAI K. ET AL.: "Roles as metabolic regulators of the non-nutrients, capsaicin and capsiate, supplemented to diets", PROC. JAPAN ACAD., vol. 79, no. 7, 2003, pages 207 - 212, XP007909041, DOI: doi:10.2183/pjab.79b.207 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2629774A4 (en) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON A CHIMIOSENSORIAL RECEPTOR LIGAND
WO2013031729A1 (en) * 2011-08-26 2013-03-07 国立大学法人大阪大学 Prophylactic/therapeutic agent for cardiovascular complications of diabetes
JPWO2013031729A1 (en) * 2011-08-26 2015-03-23 国立大学法人大阪大学 Prophylactic / therapeutic agent for diabetic cardiovascular complications
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Similar Documents

Publication Publication Date Title
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2009063222A3 (en) Solid compositions
WO2009006095A3 (en) Dual portion lozenge dosage form
WO2011107755A3 (en) Immediate/delayed drug delivery
WO2008052044A3 (en) Use of derivatives of propofol for treating diseases associated with oxidative stress
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2009008006A3 (en) Pharmaceutical compositions for gastrointestinal drug delivery
WO2011079239A3 (en) Combination tablet with chewable outer layer
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2009032870A3 (en) Method to ameliorate oxidative stress and improve working memory via pterostilbene administration
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2012092594A3 (en) Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
WO2010066749A3 (en) Ulipristal acetate tablets
NZ589469A (en) Niacin and NSAID combination for reducing niacin-induced flushing
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
MX2010003439A (en) Pharmaceutical combination of aliskiren and valsartan.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2009522376A5 (en)
WO2008105533A1 (en) Adiponectin secretion-stimulating agent comprising capsinoid compound
UA103756C2 (en) Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP